OrbiMed’s Janux Therapeutics JANX Stock Holding History

OrbiMed’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.06M	Sell	524,700 -458,900	-47%	-$6.65M	0.15%	89
2026 Q1	$13.7M	Sell	983,600 -970,826	-50%	-$13.3M	0.27%	71
2025 Q4	$27M	Buy	1,954,426 +188,326	+11%	+$4.43M	0.55%	51
2025 Q3	$43.2M	Buy	1,766,100 +555,800	+46%	+$13.5M	1.01%	34
2025 Q2	$28M	Buy	1,210,300 +451,734	+60%	+$11.9M	0.7%	38
2025 Q1	$20.5M	Hold	758,566	–	–	0.49%	43
2024 Q4	$40.6M	Sell	758,566 -500,000	-40%	-$26.4M	0.84%	35
2024 Q3	$57.2M	Sell	1,258,566 -1,721,262	-58%	-$74.9M	1.04%	28
2024 Q2	$125M	Sell	2,979,828 -1,295,725	-30%	-$60.8M	2.46%	10
2024 Q1	$161M	Buy	4,275,553 +957,626	+29%	+$20.9M	2.95%	8
2023 Q4	$35.6M	Hold	3,317,927	–	–	0.71%	50
2023 Q3	$33.4M	Buy	3,317,927 +481,541	+17%	+$5.55M	0.71%	53
2023 Q2	$33.7M	Hold	2,836,386	–	–	0.61%	52
2023 Q1	$34.3M	Hold	2,836,386	–	–	0.67%	47
2022 Q4	$37.4M	Hold	2,836,386	–	–	0.71%	51
2022 Q3	$38.4M	Hold	2,836,386	–	–	0.71%	53
2022 Q2	$34.6M	Hold	2,836,386	–	–	0.63%	50
2022 Q1	$40.7M	Hold	2,836,386	–	–	0.66%	45
2021 Q4	$56M	Sell	2,836,386 -630,000	-18%	-$13.2M	0.72%	46
2021 Q3	$75M	Hold	3,466,386	–	–	0.82%	37
2021 Q2	$86.5M	Buy	+3,466,386	New	+$77.2M	0.87%	37

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

OrbiMed's JANX Position: Q2 2026 in Review

OrbiMed reduced its Janux Therapeutics (JANX) stake by 47% in Q2 2026, selling an estimated $6.65M and leaving 524,700 shares worth $8.06M. The position accounts for 0.15% of the portfolio, ranked #89.

OrbiMed first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $161M in Q1 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

OrbiMed held 524,700 shares of Janux Therapeutics worth $8.06M as of Q2 2026.
OrbiMed sold 458,900 Janux Therapeutics shares in Q2 2026, an estimated $6.65M.
Janux Therapeutics made up 0.15% of OrbiMed's portfolio in Q2 2026, its #89 holding.
OrbiMed first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
OrbiMed's Janux Therapeutics position peaked at $161M in Q1 2024.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.